An investigational C5a receptor inhibitor, avacopan, was effective as a steroid-sparing induction treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in a phase III trial ...

Treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and renal disease with the oral C5a receptor inhibitor avacopan (Tavneos, ChemoCentryx) provides significant recovery ...

Inhibition of complement fragment C5a with an investigational drug called avacopan demonstrated efficacy against antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and might provide an ...

Avacopan, an investigational oral inhibitor of complement activation, is efficacious and safe for treating antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, based on the results of the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. To compare avacopan (CCX168, ChemoCentryx) with a ...

Investigators conducted a subgroup analysis of patients with eGFR values of 20 mL/min/1.73 m2 or less in the phase 3 ADVOCATE trial. Avacopan, an orally administered C5a receptor inhibitor approved ...

Please provide your email address to receive an email when new articles are posted on . The FDA has set a Prescription Drug User Fee Act goal date of July 7, 2021, to review the application for the ...

ST. GALLEN, Switzerland & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ:CCXI) today announced positive ...

Avacopan is an orally-administered, small molecule designed to selectively block the complement 5a receptor on destructive inflammatory cells such as blood neutrophils. The Food and Drug ...

Real-world study showed that 91% of patients with ANCA-associated vasculitis had clinical remission at 52 weeks after the start of avacopan therapy. Patients treated with avacopan for ANCA-associated ...

Pivotal trial demonstrated avacopan’s statistical superiority in sustaining remission at 52 weeks over the glucocorticoid-containing standard-of-care therapy MOUNTAIN VIEW, Calif., June 03, 2020 ...